{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:34:24Z","timestamp":1777905264428,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004914","name":"Ferring Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004914","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s41669-023-00429-8","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T10:01:34Z","timestamp":1690020094000},"page":"851-860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US\u00a0Predicted High-Responder Patients: A Cost-Comparison Analysis"],"prefix":"10.1007","volume":"7","author":[{"given":"Andrew","family":"Khair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tray","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Markert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten R\u00f8dseth","family":"Bars\u00f8e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurang S.","family":"Daftary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick W.","family":"Heiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"issue":"8","key":"429_CR1","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1093\/humrep\/deab107","volume":"36","author":"ML Eisenberg","year":"2021","unstructured":"Eisenberg ML, Thoma ME, Li S, McLain AC. Trends in time-to-pregnancy in the USA: 2002 to 2017. Hum Reprod. 2021;36(8):2331\u20138.","journal-title":"Hum Reprod"},{"key":"429_CR2","doi-asserted-by":"crossref","unstructured":"Martin JA, Hamilton BE, Osterman MJK. Births in the United States, 20202021. https:\/\/stacks.cdc.gov\/view\/cdc\/109213. Accessed 12 May 2022.","DOI":"10.15620\/cdc:119632"},{"issue":"10","key":"429_CR3","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1093\/humrep\/dex267","volume":"32","author":"YS Khandwala","year":"2017","unstructured":"Khandwala YS, Zhang CA, Lu Y, Eisenberg ML. The age of fathers in the USA is rising: an analysis of 168 867 480 births from 1972 to 2015. Hum Reprod. 2017;32(10):2110\u20136.","journal-title":"Hum Reprod"},{"key":"429_CR4","first-page":"1","volume":"21","author":"TJ Matthews","year":"2009","unstructured":"Matthews TJ, Hamilton BE. Delayed childbearing: more women are having their first child later in life. NCHS Data Brief. 2009;21:1\u20138.","journal-title":"NCHS Data Brief"},{"issue":"6","key":"429_CR5","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/humupd\/dmx022","volume":"23","author":"H Levine","year":"2017","unstructured":"Levine H, J\u00f8rgensen N, Martino-Andrade A, Mendiola J, Weksler-Derri D, Mindlis I, et\u00a0al. Temporal trends in sperm count: a systematic review and meta-regression analysis. Hum Reprod Update. 2017;23(6):646\u201359.","journal-title":"Hum Reprod Update"},{"issue":"3","key":"429_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6703a1","volume":"67","author":"S Sunderam","year":"2018","unstructured":"Sunderam S, Kissin DM, Crawford SB, Folger SG, Boulet SL, Warner L, et\u00a0al. Assisted reproductive technology surveillance\u2014United States, 2015. MMWR Surveill Summ. 2018;67(3):1\u201328.","journal-title":"MMWR Surveill Summ"},{"issue":"4","key":"429_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7104a1","volume":"71","author":"S Sunderam","year":"2022","unstructured":"Sunderam S, Kissin DM, Zhang Y, Jewett A, Boulet SL, Warner L, et\u00a0al. Assisted reproductive technology surveillance\u2014United States, 2018. MMWR Surveill Summ. 2022;71(4):1\u201319.","journal-title":"MMWR Surveill Summ"},{"issue":"2","key":"429_CR8","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/AOG.0000000000001419","volume":"128","author":"DM Kissin","year":"2016","unstructured":"Kissin DM, Boulet SL, Jamieson DJ. Fertility treatments in the United States: improving access and outcomes. Obstet Gynecol. 2016;128(2):387\u201390.","journal-title":"Obstet Gynecol"},{"key":"429_CR9","unstructured":"RESOLVE: The National Infertility Association. Insurance coverage by state 2022. https:\/\/resolve.org\/learn\/financial-resources-for-family-building\/insurance-coverage\/insurance-coverage-by-state\/."},{"key":"429_CR10","unstructured":"American Society for Reproductive Medicine. Is in vitro fertilization expensive? 2022. https:\/\/www.reproductivefacts.org\/faqs\/frequently-asked-questions-about-infertility\/q06-is-in-vitro-fertilization-expensive\/."},{"issue":"5","key":"429_CR11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.fertnstert.2007.10.038","volume":"91","author":"AO Hammoud","year":"2009","unstructured":"Hammoud AO, Gibson M, Stanford J, White G, Carrell DT, Peterson M. In vitro fertilization availability and utilization in the United States: a study of demographic, social, and economic factors. Fertil Steril. 2009;91(5):1630\u20135.","journal-title":"Fertil Steril"},{"issue":"2","key":"429_CR12","doi-asserted-by":"publisher","first-page":"hoaa009","DOI":"10.1093\/hropen\/hoaa009","volume":"2020","author":"E Bosch","year":"2020","unstructured":"Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Ovarian Stimulation T, et\u00a0al. ESHRE guideline: ovarian stimulation for IVF\/ICSI(\u2020). Hum Reprod Open. 2020;2020(2):hoaa009.","journal-title":"Hum Reprod Open."},{"key":"429_CR13","doi-asserted-by":"crossref","unstructured":"Huang JYJ, Rosenwaks Z. Assisted reproductive techniques. In: Rosenwaks Z, Wassarman PM, editors. Human fertility: methods and protocols. New York: Springer; 2014. p. 171\u2013231.","DOI":"10.1007\/978-1-4939-0659-8_8"},{"key":"429_CR14","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization\/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril. 2002;78(3):520-8.","DOI":"10.1016\/S0015-0282(02)03250-8"},{"issue":"12","key":"429_CR15","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/humrep\/del284","volume":"21","author":"AN Andersen","year":"2006","unstructured":"Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006;21(12):3217\u201327.","journal-title":"Hum Reprod"},{"issue":"3","key":"429_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.fertnstert.2011.12.016","volume":"97","author":"P Devroey","year":"2012","unstructured":"Devroey P, Pellicer A, Nyboe Andersen A, Arce JC. A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril. 2012;97(3):561\u201371.","journal-title":"Fertil Steril"},{"issue":"2","key":"429_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.fertnstert.2020.03.029","volume":"114","author":"CA Witz","year":"2020","unstructured":"Witz CA, Daftary GS, Doody KJ, Park JK, Seifu Y, Yankov VI, et\u00a0al. Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection. Fertil Steril. 2020;114(2):321\u201330.","journal-title":"Fertil Steril"},{"issue":"3","key":"429_CR18","first-page":"257","volume":"1","author":"JC Robins","year":"2020","unstructured":"Robins JC, Khair AF, Widra EA, Alper MM, Nelson WW, Foster ED, et\u00a0al. Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer-High Responder (MEGASET-HR) trial. F S Rep. 2020;1(3):257\u201363.","journal-title":"F S Rep."},{"issue":"1","key":"429_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et\u00a0al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II Good Practices Task Force. Value Health. 2022;25(1):10\u201331.","journal-title":"Value Health"},{"key":"429_CR20","unstructured":"U.S. Bureau of Labor Statistics. Databases, tables & calculators by subject 2022. https:\/\/www.bls.gov\/data\/. Accessed 19 June 2023."},{"issue":"1","key":"429_CR21","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.fertnstert.2013.09.005","volume":"101","author":"GM Chambers","year":"2014","unstructured":"Chambers GM, Hoang VP, Sullivan EA, Chapman MG, Ishihara O, Zegers-Hochschild F, et\u00a0al. The impact of consumer affordability on access to assisted reproductive technologies and embryo transfer practices: an international analysis. Fertil Steril. 2014;101(1):191-8.e4.","journal-title":"Fertil Steril"},{"issue":"3","key":"429_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/humupd\/8.3.265","volume":"8","author":"J Collins","year":"2002","unstructured":"Collins J. An international survey of the health economics of IVF and ICSI. Hum Reprod Update. 2002;8(3):265\u201377.","journal-title":"Hum Reprod Update"},{"issue":"5","key":"429_CR23","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/S0015-0282(03)02185-X","volume":"80","author":"A Lloyd","year":"2003","unstructured":"Lloyd A, Kennedy R, Hutchinson J, Sawyer W. Economic evaluation of highly purified menotropin compared with recombinant follicle-stimulating hormone in assisted reproduction. Fertil Steril. 2003;80(5):1108\u201313.","journal-title":"Fertil Steril"},{"issue":"4","key":"429_CR24","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.fertnstert.2008.01.034","volume":"91","author":"J Wechowski","year":"2009","unstructured":"Wechowski J, Connolly M, Schneider D, McEwan P, Kennedy R. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha. Fertil Steril. 2009;91(4):1067\u201376.","journal-title":"Fertil Steril"},{"issue":"1","key":"429_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40258-017-0361-7","volume":"16","author":"P Barriere","year":"2018","unstructured":"Barriere P, Porcu-Buisson G, Hamamah S. Cost-effectiveness analysis of the gonadotropin treatments HP-hMG and rFSH for assisted reproductive technology in France: a Markov model analysis. Appl Health Econ Health Policy. 2018;16(1):65\u201377.","journal-title":"Appl Health Econ Health Policy"},{"issue":"11","key":"429_CR26","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1080\/00016340802460305","volume":"87","author":"CAM Bouwmans","year":"2008","unstructured":"Bouwmans CAM, Lintsen BAME, Al M, Verhaak CM, Eijkemans RJC, Habbema JDF, et\u00a0al. Absence from work and emotional stress in women undergoing IVF or ICSI: an analysis of IVF-related absence from work in women and the contribution of general and emotional factors. Acta Obstet Gynecol Scand. 2008;87(11):1169\u201375.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"7","key":"429_CR27","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.fertnstert.2013.01.145","volume":"99","author":"AK Wu","year":"2013","unstructured":"Wu AK, Elliott P, Katz PP, Smith JF. Time costs of fertility care: the hidden hardship of building a family. Fertil Steril. 2013;99(7):2025\u201330.","journal-title":"Fertil Steril"},{"key":"429_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1093\/hropen\/hoz004","volume":"2019","author":"Z Li","year":"2019","unstructured":"Li Z, Wang AY, Bowman M, Hammarberg K, Farquhar C, Johnson L, et\u00a0al. Cumulative live birth rates following a \u2018freeze-all\u2019 strategy: a population-based study. Hum Reprod Open. 2019;2019:2.","journal-title":"Hum Reprod Open"},{"key":"429_CR29","unstructured":"Valencia Z, Bozzi D, Sen A, Martin K. Health Care Cost Institute: the price of childbirth in the U.S. tops $13,000 in 2020. 2022. https:\/\/healthcostinstitute.org\/hcci-research\/the-price-of-childbirth-in-the-u-s-tops-13-000-in-2020. Accessed 19 June 2023."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-023-00429-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T08:16:14Z","timestamp":1693469774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-023-00429-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1007\/s41669-023-00429-8","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,22]]},"assertion":[{"value":"6 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Ferring Pharmaceuticals who provided support for the model development and medical writing for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AK, MM, CB, GD, and PH are employees of Ferring Pharmaceuticals. TB is an employee of Health Economics and Outcomes Research Ltd. who received fees from Ferring Pharmaceuticals in relation to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The datasets generated during the current study are not publicly available but are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"TB, MM, AK, CB, GD, and PH have been involved in study design and analysis plan from inception to completion. TB was responsible for data analysis. All authors contributed to interpretation of the results, preparation, and review of the manuscript, and approval of the final manuscript for publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This model was developed in Microsoft Excel 365<sup>\u00ae<\/sup> using Visual Basic for Application (VBA) code, which is not publicly available.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability (software application or custom code)"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}